We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App





Direct, Cost-Effective COVID-19 Tests Identify UK/South African SARS-CoV-2 Variant and Reduces Test Time from Days to Hours

By LabMedica International staff writers
Posted on 19 Mar 2021
Print article
Illustration
Illustration
Scientists have developed direct rapid cost-effective COVID-19 tests that successfully identify the UK or South African variant of the SARS-CoV-2 virus.

The tests developed by scientists at the Ben-Gurion University of the Negev (Be'er Sheva, Israel) reduce the time needed to determine whether an infection is caused by a variant from days to hours. Comparatively, current tests for the UK and South African coronavirus variants are either expensive, time-consuming, or indirect. The current standard for coronavirus variants testing is sequencing the entire virus genome, which is expensive and time-consuming.

The new recently-developed RT-qPCR rapid tests are based on the gene deletion that differentiates the variants from the original SARS-CoV-2 strain. The scientists held trials of their tests on sewage samples from Beer-Sheva and successfully detected the UK variant but not the South African variant, which corresponded to the variants prevalent in Israel at the time.
"My lab has been working hard throughout this pandemic to provide early warning and detection tools. Our detection system of corona in wastewater successfully completed a pilot program in 14 cities around Israel," said Prof. Ariel Kushmaro who supervised the development of the tests. "We continue to refine our research in service to humankind."

Related Links:
Ben-Gurion University of the Negev

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Amoebiasis Test
ELI.H.A Amoeba

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The breakthrough could result in a higher success rate using a simple oral swab test before IVF (Photo courtesy of Shutterstock)

POC Oral Swab Test to Increase Chances of Pregnancy in IVF

Approximately 15% of couples of reproductive age experience involuntary childlessness. A significant reason for this is the growing trend of delaying family planning, a global shift that is expected to... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.